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Abstract
Cleavage factor IA (CF IA), cleavage and polyadenylation factor (CPF), constitute major protein complexes required for pre-
mRNA 39 end formation in yeast. The Clp1 protein associates with Pcf11, Rna15 and Rna14 in CF IA but its functional role
remained unclear. Clp1 carries an evolutionarily conserved P-loop motif that was previously shown to bind ATP.
Interestingly, human and archaean Clp1 homologues, but not the yeast protein, carry 59 RNA kinase activity. We show that
depletion of Clp1 in yeast promoted defective 39 end formation and RNA polymerase II termination; however, cells
expressing Clp1 with mutant P-loops displayed only minor defects in gene expression. Similarly, purified and reconstituted
mutant CF IA factors that interfered with ATP binding complemented CF IA depleted extracts in coupled in vitro
transcription/39 end processing reactions. We found that Clp1 was required to assemble recombinant CF IA and that certain
P-loop mutants failed to interact with the CF IA subunit Pcf11. In contrast, mutations in Clp1 enhanced binding to the 39
endonuclease Ysh1 that is a component of CPF. Our results support a structural role for the Clp1 P-loop motif. ATP binding
by Clp1 likely contributes to CF IA formation and cross-factor interactions during the dynamic process of 39 end formation.
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Introduction
In eukaryotes, processing of primary transcripts is essential for
RNAs to acquire biological function. Maturation of mRNAs
includes formation a 7-methyl-guanosine cap modification at the
59 end and the addition of a poly(A) tail to the 39 end. Maturation
at the 39 end affects the release of the RNA from the site of
transcription, the efficiency of translation and the susceptibility to
nucleolytic degradation [1]. The process of 39 end formation is
functionally linked to transcription by RNA polymerase II and
involves dynamic interactions of processing factors with the CTD
domain of the polymerase [2].
Pre-mRNA 39 end formation is initiated by endonucleolytic
cleavage at the poly (A) site, which is tightly coupled to
polyadenylation of the upstream cleavage product [1,3]. In yeast,
activities associated with cleavage factor IA (CF IA), cleavage
factor IB (CFI B), and cleavage and polyadenylation factor (CPF)
factors are sufficient to reconstitute both steps of the reaction in
vitro [1,3]. The protein complement of this complex machinery has
been well characterized: CFI B consist of a single subunit Hrp1
[4,5] and CF IA is comprised of the four subunits Rna14, Rna15,
Pcf11 and Clp1 [6,7,8]. CPF consists of some fifteen subunits [9]
and several sub-complexes of this factor have been characterized:
Cleavage factor II (CF II) [10], which consists of Yhh1/Cft1, Pta1,
Ydh1/Cft2, and the 39 endonuclease Ysh1/Brr5 [11,12];
polyadenylation factor I (PF I), which contains all CF II subunits,
the poly(A) polymerase Pap1, Pfs1, Pfs2, Fip1 and Yth1 [13]; and
the APT sub-complex in which Pti1, Ref2, Syc1, Swd2, Ssu72,
Glc7 associate with PF I via the Pta1 subunit [14].
The yeast Clp1 protein (which will be referred to solely as ‘Clp1’
for the remainder of this manuscript, while homologous proteins
from other organisms will carry a prefix), a subunit of CF IA, is
encoded by an essential gene that has evaded detailed study to date.
Structural analysis of Clp1 in association with a fragment of its CF
IA interaction partner Pcf11 revealed a WalkerA or P-loop domain
followed by switch I and switch II domains in the central part of the
protein [15]. Clp1 was found to be associated with ATP but
attempts failed to demonstrated ATP hydrolysis by the protein [15].
Several homologues of yeast Clp1 have been previously
characterized including human [16], plant [17] and archaeal
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cleavage factor II (CF IIm) complex along with hPcf11 [16].
Immunodepletion of hClp1 in HeLa cells eliminated cleavage
activity but had no effect on polyadenlyation [16]. Through assays
of RNA kinase activity hClp1 has been shown to have 59 OH
polynucleotide kinase activity with a preferences for RNA
compared to DNA [19,20]. hClp1 was able to complement
mutations in the RNA kinase module of tRNA ligases from yeast
and plant that act during tRNA splicing but it remains unclear
whether the protein plays a similar role in human cells [20]. In
archaea characterisation of Pyrococcus horikosii Clp1 showed that it
too is a 59OH polynucleotide kinase that can perform the kinase
step during yeast tRNA splicing [18]. Despite their structural and
sequence similarities hClp1 can not rescue lethality associated with
a deletion of the CLP1 locus in yeast [20]. This evidence taken
along with the fact that Clp1 has no detectable RNA kinase activiy
in vitro [20] and that mutations in ATP-binding site of Clp1 do not
affect yeast viability, it would seem that hClp1 and Clp1 are not
functional orthologs [20].
Here, we analyzed the role of Clp1 during the process of pre-
mRNA 39 end formation. Consistent with the notion that the
protein is an essential component of the CF IA factor, depletion of
Clp1 in cells caused defective 39 end formation and transcriptional
read-through. However, the P-loop motif and ATP binding
appear to play only a minor role for these functions of Clp1. Our
results support a structural role for ATP binding to Clp1, which
promotes protein interactions required for assembly of the CF IA
complex and which contributes to cross-factor interactions during
pre-mRNA processing.
Results and Discussion
Cellular depletion of Clp1 interferes with 39 end
formation and RNAP II transcription termination
Yeast Clp1 is known to be involved in 39end processing but its
precise role remained unclear [7,21]. We sought to deplete the
protein from cells and to determine the resulting effects on gene
expression. Since Clp1 is essential for vegetative growth we chose
to construct a strain in which the protein could be conditionally
depleted. Figure 1A outlines a plasmid-borne construct, which was
expressed in haploid strains lacking the chromosomal copy of the
CLP1 gene. In the presence of galactose an in-frame fusion of
ubiquitin, the HA-epitope tag and Clp1 was expressed (Ubi-R-
HA-Clp1) [22,23]. Cleavage of the ubiquitin moiety through
cellular deubiquitylating enzyme generated protein that carried an
arginine at its amino-terminus and thus, according to the N-end
rule, rendered the protein unstable [22]. Strains expressing GAL-
UBI-R-HA-CLP1 grew without apparent growth defect on
galactose medium indicating that the Ubi-R-HA-Clp1 fusion
protein was functional (Fig. 1A). In contrast, no growth of the
strain was observed in the presence of glucose (YPD), indicating
that the protein was efficiently depleted. This was verified by
Western blotting using antibodies directed against the HA-tag.
Figure 1B shows a strong decrease in Ubi-R-HA-Clp1 protein
following growth in YPD for four hours and almost complete
depletion after eight hours.
To determine the effects of Clp1 depletion on gene expression,
different classes of RNA Pol II transcripts were analyzed by
Northern blot (Fig. 1C). We initially probed for expression of the
UBI-R-HA-CLP1 transcript that was over-expressed in galactose (0
hrs in YPD) and strongly reduced after shift to YPD (4 and 8 hrs).
In the wild-type expression of the shorter CLP1 mRNA was
detected, which was unaltered in the presence of galactose. The
ACT1 gene carries a cluster of alternative poly (A) sites in its
39UTR [24]. In wild-type strains the most proximal and stronger
pA site is used predominantly but mutations within 39 end
processing factors [25] or the chemical inhibitor cordycepin [26]
promote usage of the distal pA-sites. Similarly, Clp1 depletion
correlated with an accumulation of longer transcripts that resulted
from the use of distal pA-sites. The intron-containing ASC1 gene
also contains alternative poly(A) sites [26]. While ASC1 mRNA
levels were strongly reduced after eight hours YPD, preferred
usage of more distal poly(A) sites was apparent at earlier time
points. The intron containing CYH2 gene does not carry closely
spaced alternative poly(A) sites, but CYH2 mRNAs are strongly
extended in the presence of the 39 end formation inhibitor
cordycepin [26]. Similarly, we observed extended CYH2 RNAs
following Clp1 depletion. Pre-mRNA splicing of CYH2 transcripts
is slow allowing for ample accumulation of the unspliced precursor
[27]. Stable levels of pre-CYH2 following Clp1 depletion suggested
that the protein was not required for pre-mRNA splicing. Finally,
we looked at RNAP II transcripts that are expressed in a Nrd1-
dependent pathway [28]. Nrd1p controls its own expression
through regulated premature termination [29]. As Clp1 becomes
depleted an increase in NRD1 transcripts was observed, suggesting
that Nrd1 auto-regulation was defective. Furthermore, we
observed the accumulation of extended NRD1 transcripts, which
likely corresponded to NRD1-MRPL17 read-through transcripts
[28,30]. Transcriptional read-through was also detected at the
snR13 locus resulting in strong accumulation of extended snR13-
TRS31 RNAs after eight hours in YPD. Finally, we observed read-
through at the terminator for the SRG1 cryptic unstable transcript
(CUT) resulting in the accumulation of bicistronic SRG1-SER3
RNAs. Taken together, our results show that depletion of Clp1
resulted in defective expression of all analyzed RNAP II
transcription units. Both poly(A)-dependent and poly(A)-indepen-
dent 39 end formation pathways were affected resulting in deficient
transcriptional termination. Interestingly, both of these pathways
also require Pcf11, whereas this remains unclear for the CF IA
components Rna14 and Rna15 [31,32]; our observations point
towards a possible requirement for a functional Pcf11-Clp1 dimer
at polyA dependent and independent terminators.
Clp1 mediates protein interactions with CF IA and CPF
Previous work revealed that Clp1 binds to the Pcf11 subunit of
CF IA and the Ysh1 subunit of CPF [21,25]. To further
understand the role of Clp1 in 39end formation we wished to
determine the domains that were mediating interactions. For this
purpose we dissected the role of three Clp1 domains (Fig. 2A): a N-
terminal domain (NTD; amino-acids 1 to 100), a central domain
(CD; amino-acids 101 to 341) and a C-terminal domain (CTD;
amino-acids 342 to 446). The central domain contains the P-loop
motif, the switch I and switch II motif as well as the base binding
loop, which are involved in nucleotide binding [15]. Pull-down
experiments were performed with GST-fusion proteins and in vitro
translated,
35S-labelled full-length Clp1 or fragments encompass-
ing CD, NTD-CD, CTD-CD, NTD, or CTD domains (Fig. 2B).
We found that GST-Pcf11 bound strongly to full-length Clp1 and
weakly to isolated Clp1 domains. The latter weak interactions
were observed with fragments containing the CD but not with
NTD and CTD peptides. These results suggested that efficient
binding to Pcf11 required full-length Clp1 and that the CD was
involved in the interaction between these two CF IA subunits. In
contrast, GST-Ysh1 and GST-Rna14 bound to all CD-containing
domains of Clp1 and the CTD but not to the NTD. Thus, the
interactions between Ysh1, Rna14 and Clp1 involve both the CD
and the CTD. With GST-Rna15 significant pull-down was only
observed for the CTD fragment. Since no binding was detected
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PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e29139Figure 1. Effects of Clp1 depletion on gene expression. (A) Schematic presentation of the Clp1 fusion gene, which is expressed under the
control of GAL10 promoter. Encoded are an amino-terminal ubiquitin moiety fused in frame to Clp1 together with an HA-tag. Removal of the
ubiquitin moiety by cellular deubiquitylases results in a protein with an arginine (R) at the amino-terminus creating an unstable protein that is
targeted for degradation by the proteasome. A strain carrying this fusion gene is viable on YPGal medium but not on YPD, which contains repressive
glucose as sole carbon source. (B) Western Blot of total extracts obtained from wild-type and GAL-UBI-R-HA-CLP1 expressing strains following growth
in YPD for the indicated times. Western blots were decorated with antibody against the HA-tag. Ponceau S staining served as control for equal
loading. (C) Northern analysis of total RNAs obtained from wild-type and GAL-UBI-R-HA-CLP1 expressing strains following growth in YPD for the
indicated times. RNAs were detected with random prime labeled probes directed against the open reading frames as indicated on the left of each
panel. The asterisk in the first panel marks a likely degradation product of the UBI-R-HA-CLP1 mRNA. In CYH2 and NRD1 panels ‘ext’ denotes 39
extended transcripts. 18S rRNA was detected with an end-labeled oligonucleotide and was used as control for equal loading. Schematically depicted
on the right are features of analyzed and neighbouring genes with arrows indicating sites of 39 end cleavage and polyadenylation.
doi:10.1371/journal.pone.0029139.g001
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PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e29139Figure 2. Clp1 mediates interactions between CF IA and CPF factors. (A) Schematic presentation of the yeast Clp1 domain structure.
Indicated are N-terminal domain (NTD), central domain (CD) and the C-terminal domain (CTD), as well as the locations of mutations analyzed in this
study. The lower part of the panel shows Clp1 fragments, which were analyzed in binding studies. (B) GST pull-down experiments with GST, GST-
Pcf11, GST-Ysh1, GST-Rna14 and GST-Rna15 and in vitro translated and [
35S]-methionine-labeled proteins as indicated on the left. Input shows 10% of
total radioactive material included in the binding reactions. (C) GST pull-down experiments using the indicated GST-fusion proteins and in vitro
translated and [
35S]-methionine-labeled full length wild-type and mutant Clp1 proteins as indicated on the right. (D) GST pull-down experiment with
GST-Ysh1 and in vitro translated and [
35S]-methionine-labeled proteins. All binding reactions contained labeled Pta1 as well as increasing
concentrations of wild-type and mutant Clp1 proteins as indicated. On separate gels (not shown) it was ensured that equivalent amounts of
radioactive protein was included in reactions where binding of wild-type Clp1 protein was compared to D161A and K136A T137A mutants.
doi:10.1371/journal.pone.0029139.g002
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unclear. Taken together, these results revealed that the Clp1-CD is
involved in mediating interactions with subunits of both CF IA
and CPF.
Since the P-loop motif of Clp1 is contained within the CD
domain we wished to determine whether an intact P-loop was
required for binding to Pcf11 and Ysh1. For this purpose GST
pull-down experiments were performed with wild-type and mutant
Clp1 proteins (Fig. 2C). Specifically, we tested single mutations
within the P-loop motif (Q133D, K136N, T137A) and the switch I
region (D161A), the double mutation K136A T137A and the
triple mutation loop exchange (G132P Q133D T135V); the latter
mutations reconstitute amino acids of the hClp1 P-loop motif
within the yeast protein. We found that binding to GST-Pcf11 was
completely lost with K136A or T137A single mutations and
K136A T137A double mutations whereas binding efficiency was
compromised with the switch I mutation D161A. In contrast,
binding was efficient with Q133D and loop exchange mutants.
Interestingly, GST-Ysh1 interacted with all tested Clp1 proteins
(Fig. 2C). However, in multiple experiments binding was
consistently weaker with wild-type Clp1 compared to any of the
tested Clp1 mutants. This effect was enhanced when binding
reactions also contained the CPF subunit Pta1, which directly
binds to GST-Ysh1 (Fig. 2D, lane 1). Under these conditions the
weaker binding of wild-type Clp1 (lanes 3 and 4) appeared
aggravated compared to D161A (lanes 5 and 6) and K136A
T137A Clp1 variants (lanes 7 and 8). Together these data suggest
that mutations within the Clp1 P-loop caused structural changes
that enhanced binding to the 39 endonuclease Ysh1.
Next, we extended these interaction studies to the remaining CF
IA subunits Rna14 and Rna15 (Fig. 2C). While no interactions
could be detected between Clp1 proteins and GST-Rna15,
binding prevailed with GST-Rna14. Notably, interaction signals
in the latter experiments were relatively weak and we found,
similarly to the experiments with GST-Ysh1, that the mutant Clp1
proteins bound slightly better compared to the wild-type. Finally,
we tested interactions with the mRNP export factor Yra1, which
was recently found to bind to Pcf11 adjacent to the Clp1
interaction site [33]. However, no interactions were detected
between Clp1 proteins and GST-Yra1.
Our interaction studies suggested that the central domain of
Clp1, which included the P-loop motif, modulated binding to 39
end factors Pcf11, Ysh1 and Rna14. To test whether ATP binding
by the P-loop played a role in these interactions we chose to
assemble CF IA entirely from heterologously expressed subunits
and to test the nucleotide binding state of Clp1 in the context of
the reconstituted factors. In these experiments we first immobilized
GST-Pcf11DN288 (lacking the amino-terminal domain that
mediates binding to the RNAP II CTD) on glutathione sepharose
and added His6-Clp1 and preformed His6-Rna14/Rna15 dimers.
Reconstitution occurred efficiently when all four CF IA subunits
were present [34]. In contrast, we were not successful in isolating
CF IA factor when Clp1 protein was omitted suggesting that Clp1
was required for assembly of CF IA with recombinant subunits in
vitro (data not shown).
Next, we wished to produce recombinant CF IA factors with
mutant Clp1 proteins that did not interact with Pcf11 in pull-
downs (see Fig. 2C). However, attempts to over-express and purify
CF IA carrying Clp1 mutated at single positions K136A, T137A,
and D161A or at both K136A and T137A, failed due to low
solubility of proteins in E. coli (data not shown). We speculate that
compromised ATP-binding capacity caused aberrant protein
folding and aggregation. In contrast, we obtained CF IA carrying
wild-type Clp1, Clp1 Q133D and the loop exchange triple mutant
(data not shown). We used the reconstituted factors to determine
the presence and identity of bound nucleotides. For this purpose
protein samples were precipitated and applied to a ProntoSIL C18
reverse phase column. The column was developed with 50 mM
potassium phosphate buffer and nucleotide elution was monitored
by measuring absorption at 254 nm (see Materials and Methods).
These analyses revealed that 57% of the obtained CF IA
containing wild-type Clp1 was ATP bound, 43% was nucleotide
free and none was bound to ADP (Table 1). The factor carrying
the Q133D mutation distributed in comparably sized nucleotide-
free, ATP- and ADP-bound fractions. Interestingly, the loop
exchange mutant showed no detectable amounts of ATP, while
47% of the samples were ADP bound and 53% did not contain
any nucleotide. It remains unclear why no ATP was associated
with CF IA carrying the loop exchange mutant. Since we could
not detect ATPase activity associated with this factor (data not
shown) we suspect that the introduced mutations changed the
nucleotide binding preference from ATP to ADP. Irrespective of
the underlying reasons, the loop exchange mutant provided us
with a source of CF IA that was devoid of ATP and which could
be functionally tested using in vitro transcription/processing
reactions (see below). The observation that the loop exchange
mutant efficiently bound to GST-Pcf11 (see Fig. 2C) and readily
assembled into recombinant CF IA factor provided strong
evidence that the presence of ATP binding was not essential for
the interaction between Clp1 and Pcf11 protein. Likewise,
interactions with Ysh1 and Rna14 are not expected to depend
on the presence of ATP since interactions occurred with the loop
exchange mutant (Fig. 2C). We interpret these data such that
ADP, which was the only nucleotide found associated with this
mutant, can functionally replace ATP to support interaction with
Pcf11, Ysh1 and Rna14. Alternatively, the nucleotide may be
entirely dispensable for Clp1 to engage in these interactions.
Gene expression in CLP1 ATP-binding mutants
We have shown that Clp1 depletion promoted defects in 39end
formation at different classes of RNAP II transcripts (Fig. 1C).
These observations raised the possibility that ATP binding by Clp1
may be required for efficient pre-mRNA processing. To
investigate this we initially used Northern blotting to analyze gene
expression in haploid yeast strains carrying chromosomal deletions
of the CLP1 gene that were complemented either with a plasmid-
borne copy of wild-type CLP1 or with alleles carrying the D161A
single and the K136A T137A double mutations. In contrast to the
depletion experiments shown in Figure 1 this approach allowed to
specifically address the role of the P-loop in gene expression.
Remarkably, no effects could be observed in the expression of
ACT1 and TRS31 mRNAs (Fig. 3A) suggesting that the Clp1 P-
loop motif and ATP binding, respectively, were not essential for
poly(A) dependent and poly(A) independent 39 end formation
pathways. We extended these analyses and performed genome-
wide expression profiling using microarrays and total RNA
obtained from the same strains that were used in Figure 3A, i.e.
wild-type, the D161A single and the K136A T137A double
mutants. Consistent with the absence of apparent growth defects
associated with the mutants [15] (data not shown), these
experiments suggested that overall gene expression in the analyzed
CLP1 mutants was comparable to wild-type (S.H. and B.D.
unpublished results). We identified less than fifty candidate genes
that were changed in their expression at least two-fold in both
mutants (S.H. and B.D. unpublished results). No significant gene
ontology terms could be associated with these genes indicating that
no specific class of genes was dependent on an intact CLP1 P-loop
motif (S.H. and B.D. unpublished results). We performed qRT-
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increased in the mutants, respectively. Figure 3B shows that levels
of five tested candidate mRNAs were reduced approximately 2-
fold. The levels of two analyzed mRNAs (PHO89 and ENB1) were
significantly elevated in the K136A T137A strain but less so in the
D161A mutant. Taken together, our experiments revealed that
mutations within the CLP1 P-loop motif that are expected to
interfere with ATP binding [20] and which diminish the
interaction with Pcf11 (Fig. 2C) resulted in minor changes in the
expression of a small number of genes.
An intact Clp1 P-loop is dispensable for 39 end formation
in vitro
To further test the role of the Clp1 P-loop and ATP binding we
used a coupled in vitro transcription/processing system based on
yeast whole cell extracts [34]. Figure 4B depicts the analyzed
transcription unit that carries five G-less cassettes that are
increasing in their length in 59 to 39 direction of the derived
RNA [34]. This construct gives rise to 84a, 84b and 100
nucleotide G-less transcripts that are encoded upstream of the
CYC1 terminator and 120, 131 and 145 nucleotide G-less
transcripts that result from transcription downstream of the
terminator [34]. Extracts were depleted of endogenous CF IA
and defects in transcription termination and in 39 end formation
were rescued by adding back CF IA that was reconstituted from
recombinant protein or that was purified from yeast, respectively
[34].
Limitations in protein solubility did not allow us to assemble
recombinant CF IA with Clp1 protein carrying the K136A T137A
mutations (see above). Therefore, we chose to express the protein
in yeast fused to a ProteinA-tag and to partially purify the
associated CF IA activity. Figure 4A shows that ProteinA-Clp1
K136A T137A co-purified with other CF IA subunits in a
stoichiometry that was comparable with wild-type ProteinA-Clp1.
Notably, the purification protocol included a final high salt wash
step (1 M KCl); thus, a compromised Clp1-Pcf11 interaction as
observed with the Clp1 K136A T137A mutant (Fig. 2C), did not
significantly disrupt the integrity of CF IA.
Next, we used a coupled in vitro transcription/39 end processing
assay [34] to analyze the activity of ProtA-purified CF IA factors
carrying wild-type or K136A T137A Clp1 proteins. To resolve
potential differences in factor activity resulting from differential
stability or purity, respectively, we used increasing amounts of KCl
during the final wash steps of affinity purification. A typical
experiment is shown in figure 4D and quantification of the results
is shown in figure 4E. Depletion of CF IA from extracts resulted in
enhanced transcriptional read-through passed the CYC1 termina-
tor increasing the levels of 120, 131 and 145 G-less cassettes
relative to the 100 cassette that is placed just 59 of the terminator
[34]; ‘no CF IA’ in figure 4D and 4E). Add-back of purified factors
rescued these phenotypes to the same extend for CF IA containing
wild-type and K136A T137A mutant Clp1 (Fig. 4D and 4E). In
addition to these transcriptional analyses we also tested 39 end
cleavage during the in vitro transcription/processing reactions using
a ligation-mediated RT-PCR approach [35]. As expected, the
extracts depleted of CF IA had compromised cleavage activity as
evidenced by the absence of RT-PCR product (poly(A) cleavage
panel in figure 4D). Add-back of wild-type and K136A T137A
factors to the reactions rescued this defect showing that 39 end
cleavage occurred efficiently with the mutant factor. To analyze
the accuracy of 39 end cleavage we performed DNA sequencing of
ten individual RT-PCR products encompassing the sites of poly(A)
addition on transcripts obtained from wild-type and mutant CF IA
supplemented reactions. In all cases processing occurred at the
major CYC1 poly(A) site demonstrating that the K136A T137A
Table 1. ATP binding status of recombinant CF IA factors.
CF IA factor nucleotide free ATP ADP
wild-type 43% 57% -
Clp1 Q133D 38% 33% 29%
Clp1 G132P Q133D T135V (loop exchange) 53% - 47%
doi:10.1371/journal.pone.0029139.t001
Figure 3. Gene expression in strains expressing Clp1 proteins carrying a mutant P-loop. (A) Northern analysis of total RNAs obtained from
wild-type and CLP1 D161A and CLP1 K136A T137A mutant strains following growth in YPD. Probes were as described in the legend of figure 1C.
(B) qRT-PCR analysis of candidate mRNAs that were identified during gene expression profiling of CLP1 D161A and CLP1 K136A T137A mutant strains.
Transcript levels are presented relative to wild-type CLP1, which was fixed at 100%. Data shown are the mean of three independent biological
replicates and error bars indicate standard deviation.
doi:10.1371/journal.pone.0029139.g003
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PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e29139Figure 4. Coupled in vitro transcription/39 end processing. (A) Western blot analysis of CF IA factors partially purified from strains expressing
ProtA-Clp1 and ProtA-Clp1 K136A T137A, respectively. Factor purification included a high salt wash (1 M KCl) of bound material to probe stability and
integrity of the protein complexes. Decreasing amounts of CF IA associated with ProtA-Clp1 or ProtA-Clp1 K136A T137A were analyzed for the
presence of the four CF IA subunits Rna15, Pcf11, Clp1 and Rna14 as indicated on the right. (B) Schematic presentation of the transcription template
that was used in transcription/39 end processing reactions in vitro. The construct includes Gal4 binding sites, a CYC1 promoter and five G-less
cassettes; the length of the cassettes in nucleotides is indicated. The CYC1 terminator has been inserted between the 100 and 120 cassettes; also
indicated are specific sequence elements (EE: efficiency element; PE: positioning element; UUE: upstream U-rich element; DUE: downstream U-rich
element; and the poly(A) site). In vitro transcription produces a 0.5 kb polyadenylated RNA and read-through transcription produces a RNA of more
than 1.3 kb length. (C) Western analysis of ProtA-Rna15 expressing whole cell extracts before and after two consecutive rounds of depletion on IgG-
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selection (data not shown). We were concerned that the 40 min
endpoints of our in vitro reactions were not suitable to resolve
potential kinetic delays in either transcription termination or 39
end cleavage that may occur with the mutant factor. To test that
we performed time-course experiments analyzing time-points as
short as 2.5 min reaction time (data not shown). However, also
these conditions did not reveal significant differences in the ability
of wild-type and K136A T137 CF IA to rescue defects in
transcription termination and 39 end processing (data not shown).
Our result suggested that a compromised P-loop motif did not
interfere with the function of Clp1 in pre-mRNA 39 end formation
and termination in vitro. To address more directly the requirement
of Clp1 ATP-binding for 39 end formation we took advantage of
the reconstituted CF IA factor that carried the Clp1 loop exchange
protein and which we found to carry ADP but not ATP (Table 1).
In vitro transcription/39 end processing experiments and 39 end
cleavage analyses were performed with reconstituted CF IA factors
as described above for ProtA-purified factors. Complementation of
CF IA depleted extracts was found to be equally efficient when
recombinant CF IA containing wild-type or loop exchange
variants of Clp1 were present (data not shown).
In summary, our in vitro analyses suggested that neither an intact
Clp1 P-loop, nor ATP binding by CF IA, respectively, were
essential for transcription termination and pre-mRNA 39 end
formation in vitro. Since mutations interfering with the P-loop
structure (K136A T137A and D161A) had only marginal effects
on gene expression in vivo we consider it unlikely that ATP
hydrolysis represents an essential functional role for Clp1 in its
association with CF IA. Our protein-interaction studies revealed,
however, that the P-loop mutations disrupted the interaction
between Clp1 and Pcf11 (Fig. 2C). Since we were not able to
assign defects in pre-mRNA processing or transcription termina-
tion to the K136A T137A containing CF IA factor we conclude
that the Clp1-Pcf11 interaction most likely plays a minor role in
the functioning of CF IA in these processes. In the light of these
results the effects of cellular Clp1 depletion on gene expression
have to be interpreted with caution. It seems possible that the
absence of Clp1 provoked indirect effects on mRNA synthesis e.g.
through interference with the stability of associated proteins, most
notably the direct interaction partners Pcf11 and Rna14.
Our analyses did not reveal evidence that would support a
functional role for ATP hydrolysis by Clp1. In contrast, several
lines of evidence point to a structural role for ATP binding to
Clp1. During protein over-expression of mutant Clp1 proteins we
consistently found that changes within the P-loop motif gave
largely insoluble protein. We interpret these observations such that
ATP binding may be required for Clp1 to adopt a properly folded
conformation and to escape aggregation. Our CF IA reconstitu-
tion experiment suggested furthermore that Clp1 is essential for
the assembly of the factor in vitro. Assuming that Clp1 indeed acts
in CF IA complex formation, why does the K136A T137A
mutation, which is deficient in binding to Pcf11, not show any
defect in mRNA synthesis or cell growth? One possible answer to
this question may be that redundant interactions between subunits
exist that cooperate to ensure efficient complex assembly. In
support of this idea we observed that Clp1 not only bound to Pcf11
but also to Rna14 (Fig. 2C).
Alternatively, Clp1 may modulate the efficiency of pre-mRNA
39 end formation in a fashion that is too subtle to be detected in
our in vivo steady-state gene expression analyses, or in transcrip-
tion/processing experiments in vitro. Since Clp1 is binding to both
CF IA and CPF subunits it is tempting to speculate that the
protein may relay dynamic interactions and conformational
rearrangements that may occur before, during or after the
catalysis of cleavage and polyadenylation. It seems particularly
intriguing that Clp1 contacts the 39 endonuclease Ysh1 and that
mutant Clp1 proteins bound better than wild-type (Fig. 2C). While
this could result from the accidental presentation of an unspecific
interaction patch, it may also point to a functionally relevant
conformational switch that is associated with the P-loop motif. In
such a scenario Clp1 may mediate alternate binding to Pcf11 and
Ysh1, respectively. Interestingly, the presence of Pta1 accentuated
the preference of Clp1 P-loop mutants to bind to Ysh1. We
anticipate that future attempts to further the understanding of
Clp1 as a component of the 39 end formation machinery will have
to be performed in the context of an extended interaction network.
Materials and Methods
Yeast strains and plasmid constructs
Yeast strains were grown in rich medium (2% bacto-tryptone,
1% yeast extract) supplemented with 2% glucose (YPD) or 2%
galactose (YPGal) as indicated in the figures. Strain used in this
study were wild-type (MATa ade2 leu2 ura3 trp1-1 his3) and
Gal10-UBI-R-HA-CLP1 (MATa ade2 leu2 ura3 trp1-1 his3
TRP1::clp1 [pGAL10-UBI-R-HA-CLP1]). Strains DClp1::kan
R;
[pRS423-wt-Clp1], DClp1::kan
R; [pRS423-Clp1 K136A T137A],
DClp1::kan
R; [pRS423 yClp1 D161A] were generously provided
by Dr. Beate Schwer [15].
Constructs and site directed mutagenesis
Plasmids used for the expression of recombinant CF IA
components for factor reconstitution included previously described
GST-Pcf11DN288, His6-Rna15/Rna14 and His6-Clp1 (pBD137)
constructs [15]. Mutants of the Clp1 protein were generated using
the QuickChange mutagenesis kit (Stratagene) and pBD137 as
template. Primers were designed and the protocol performed as
described in the manufacture’s manual. We produced the
following mutants: His6-Clp1 K136A-T137A (pSS832) His6-
agarose. Increasing amounts (1, 2 and 4 ml) of extract (XT) and of depleted extract (26depl) were resolved by SDS-PAGE and following transfer on
PVDF membrane ProtA-Rna15 was detected using an anti-HA-HRP secondary antibody that readily bound to the ProteinA moiety of the fusion
protein. Ponceau S staining of a section of the membrane is shown to demonstrate comparable loading between extract and depleted extract. (D) In
vitro transcription/39 end processing reactions with CF IA depleted extracts in with or without adding back ProtA-Clp1 and ProtA-Clp1 K136A T137A
purified CF IA factors as indicated. On the top of each panel is indicated the salt concentration (mM KCl) applied in the final wash step of the protocol
that was applied to purify CF IA factors associated with ProtA-tagged wild-type and mutant Clp1. G-less transcripts were separated on 8.3 M Urea 6%
polyacrylamide gels. Migration of the G-less transcripts is indicated on the left. Gels at the bottom of each panel show the analysis of pre-mRNA 39
end cleavage. Non-radioactive in vitro transcription reactions were performed and obtained RNAs were subjected to a ligation-mediated RT-PCR
procedure. Formation of PCR product correlates with 39 end cleavage activity and encompasses the site of poly(A) addition. (E) Quantification of the
gels shown in (D). The obtained signals were normalized to uridine-content of the cassettes and presented as percentage of G-less transcription
relative to the 100 cassette that is placed immediately upstream of the CYC1 terminator; the site of poly(A) addition has been fixed at ‘‘0’’ bp.
Termination and 39 end formation is reflected by strength of transcription downstream of the terminator, and is indicated by 120/100, 131/100 and
145/100 signal ratios.
doi:10.1371/journal.pone.0029139.g004
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T137A (pSH844), His6-Clp1 G132P Q133D T135V (loop
exchange; pSH845) and His6-Clp1 K136N (pSH828). Constructs
expressing Clp1 domains were generated by inserting PCR
fragments via oligonucleotide encoded NdeI sites into the same
site of pBD137. This generated NTD-Clp1 (amino acids 1–100;
pSS837), NTD-CD-Clp1 (amino-acids 1–341; pSS838), CD-Clp1
(amino acids 101–341; pSS839), CD-CTD-Clp1 (amino-acids
101–446; pSS840) and CTD-Clp1 (amino acids 342–446;
pSS841). GST fusion proteins were expressed with the use of
plasmids GST-Pcf11 (pSH890), GST-Ysh1 (pBD73), GST-Rna14
(pBD221), GST-Rna15 (pUL1043), GST-Yra1 (generously pro-
vided by Dr. Franc ¸oise Stutz). Constructs for the expression of
ProtA-tagged wild-type and mutant Clp1 in yeast were produced
by inserting PCR fragments via Nde1-XmaI using oligonucleotide
encoded restriction sites into the same sites of vector pNOP1::-
ProtA-TEV::ADH1 [36]. ProtA-Clp1 (pSH852), ProtA-
Clp1K136A-T137A (pUL1044) and ProtA -Clp1 D161A
(pSH1047). pGAL10-UBI-R-HA-CLP1 was produced as de-
scribed [15]. Correct nucleotide sequences were verified by
DNA sequencing on both strands.
Protein expression, CF IA reconstitution and GST
pull-down
Expression of recombinant protein and reconstitution of
recombinant CF IA was done as previously described [15]. In
vitro translated proteins were produced using the TNT-coupled
transcription-translation system and [
35S]-methionine according to
manufacturers recommendation (Promega). GST pull-downs were
performed as previously described [15]. In vitro translated proteins
were incubated with GST-fusion proteins (100 ng) for 1 h at room
temperature. The mixture was bound in a total volume of 860 ml
to 20 ml glutathione sepharose (Pharmacia) which was equilibrated
in 1 ml PBS, 0.01% NP-40 and 100 mg BSA. The matrix was
washed three times with IPP150 (20 mM Tris-HCl pH 8.0,
150 mM KCl, 0.01% NP-40). The proteins were eluted by
addition of protein loading buffer and incubation at 95uC.
Obtained proteins were separated by SDS-PAGE and visualized
by autoradiography.
RNA extraction and analysis
Total RNA was extracted from yeast strain using the hot phenol
method. Northern analyses were carried out as described [15].
PCR products covering the following ORF served as templates for
the synthesis of [
32P]-labeled probes using the random prime
labeling kit (Roche): ACT1, ASC1, CYH2, NRD1, TRS31,
SER3, SRG1-SER3. Oligonucleotide probes were labeled with
[
32P]-c-ATP and T4 polynucleotide kinase: anti-18S (CAGA-
CAAATCACTCCA). qRT-PCR analysis was carried out as
described [15]. qPCR was done on an Applied Biosystems
7900HT fast real-time PCR system using the SYBR Green PCR
Master Mix (Applied Biosystems) according to the manufacturer’s
instructions.
Coupled in vitro transcription/39end processing
Reactions were done with extracts depleted of CF IA as
previously described [15]. Purification of CF IA factors via ProtA-
Clp1 and ProtA-Clp1 K136A T137A was done as described [15].
The final wash step of the purification protocol included variable
KCl concentrations (120 mM to 1 M) as indicated in figure 4. For
the analysis of 39 end cleavage activity in vitro reactions were done
in the absence of radioactive precursors. RNA obtained from in
vitro transcription/39 end processing was extracted and subjected
to ligation-mediated linker RT-PCR as described [15].
Nucleotide analysis
To determine the identity of nucleotide bound to CF IA, high-
performance liquid chromatography analysis was performed. Prior
to sample application, 16 ml of the protein sample was precipitated
with 50% of trichloroacetic acid and incubated for 15 min on ice.
Subsequently the denatured protein was centrifuged for 10 min at
13’400 rpm on a tabletop centrifuge at 4uC. For neutralization of
the supernatant, 10 ml were mixed with 20 ml of a 2 M potassium
acetate solution. 20 ml of this solution was applied to a C18
column (ProntoSIL Hypersorb) and developed with 50 mM
potassium phosphate buffer (pH 6.8). Nucleotide elution was
monitored by absorption at 254 nm and the retention time
compared to runs of nucleotide standards. Nucleotide content was
calculated by integration of the peak areas.
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